CLINICAL_TRIALS
trial_result
· 2019-09-10
Clinical Trial Update: One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease [Phase 3]
Summary
A Phase 3 trial of delayed-release rifaximin in Crohn's disease was terminated with results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bausch Health Americas, Inc. | Conditions: Crohn's Disease | Phase 3 | Status: TERMINATED | Results posted: 2019-09-10